Elizabeth Krause on C-HIT Discussing Disparities
Last week, Connecticut Health I-Team, a grantee of the Connecticut Health Foundation (CT Health), ran an article called “Is Myriad’s Patent On Breast Cancer Genes Valid?” Reporter Barbara Puffer wrote about Myriad’scontroversial BRAC , BRCA1, and BART genetic analyses for detecting breast and other reproductive cancers. The controversy is around cost and access. From the article: “They say an additional analysis, known as BART (BRAC Analysis Rearrangement Test), is necessary, but not always accessible—especially for Hispanics, who show in Myriad testing to be at high risk for the large-rearrangement mutations. The BART test, also licensed by Myriad, costs $700 and is not widely approved for insurance coverage.”
Senior Program Officer Elizabeth Krause commented on the disparity related to Myriad. From the article:
“Elizabeth Krause, senior program officer at the Connecticut Health Foundation, which works to combat racial and ethnic health disparities, said Latinos, as well as other minorities, face multiple barriers to accessing preventative breast health care, including a lack of both health insurance and “health literacy” in understanding genetic testing options.
“A Latino woman would first have to understand her family history and then contact her insurance company to see if the test is covered, and then weigh the cost-benefit” of genetic testing, Krause said. “There are all the barriers in the world” to accessing BART or BRAC testing.”